MedTrace Logo

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)

NCT01075282 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 810

Last updated 2015-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes. Participants must also be taking metformin and glimepiride.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Glargine

DRUG

LY2189265

DRUG

Metformin

DRUG

Glimepiride

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-05-31
Completion
2012-11-30

Countries

  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Croatia
  • Czechia
  • France
  • Greece
  • Hungary
  • India
  • Italy
  • Mexico
  • Poland
  • Romania
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075282 on ClinicalTrials.gov